Kali Extracts Presents Cannabis Extract Biopharmaceutical Strategy Targeting $170 In Million Pharmaceutical Market Opportunity
April 17 2019 - 9:39AM
InvestorsHub NewsWire
Kali Extracts Presents Cannabis
Extract Biopharmaceutical Strategy Targeting $170 In Million
Pharmaceutical Market Opportunity
Dallas, TX -- April 17, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today published a presentation elaborating on
the company’s overall strategy to discover, develop and
commercialize novel therapeutics from its proprietary cannabinoid
product platform. KALY owns and operates a patented cannabis
extraction process. Following four years of research and
development, the company recently executed a strategy to bring the
resulting intellectual property (IP) into a public company as part
of a plan to capitalize its next stage of development. KALY
is that public company platform. In conjunction with that
plan, the company has recently disclosed four of its leading
research and development initiatives targeting four specific health
issues:
- Chronic
Obstructive Pulmonary Disease (COPD) - The market for COPD
treatment is anticipated to reach $14 billion by 2025;
- Type 2
Diabetes - The market for Type 2 Diabetes is expected to be a
$64 billion market by
2026;
- Cancer
Pain Management - The overall pain
management treatment market is anticipated to reach $83 billion by 2024, and
- Epilepsy
- The market for epilepsy
treatment is anticipated to reach $9 billion by 2022.
The
presentation below and incorporated into the company’s website
offers further detail on the company’s progress to date and plans
moving forward to commercialize cannabis
therapies.
Patented Cannabis Extracts
Targeting $170 In Million Pharmaceutical
Treatments
In the
fourth quarter of last year, 2018, KALY acquired NCM Biotech
(NCMB). NCMB is biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
a proprietary cannabinoid product platform in a broad range of
disease areas. In four years of operations, the company has
established a leading position in the development of plant-derived
cannabinoid therapeutics through a proven drug discovery and
patented development process. The resulting intellectual
property portfolio and the established regulatory and manufacturing
expertise have created a significant opportunity. KALY,
through its subsidiary, NCMB has a deep pipeline of additional
cannabinoid product candidates including four distinct
compounds. KALY has completed the first stage of clinical
development and testing for a Chronic Obstructive Pulmonary Disease
(COPD) therapy and is currently conducting phase one development
and trials for compounds targeting Cancer Pain Management, Type 2
Diabetes and Epilepsy.
$170 Million Cannabis Therapeutics Market
Opportunity
- Chronic
Obstructive Pulmonary Disease (COPD) - The market for COPD
treatment is anticipated to reach $14 billion by 2025;
- Type 2
Diabetes - The market for Type 2 Diabetes is expected to be a
$64 billion market by
2026;
- Cancer
Pain Management - The overall pain
management treatment market is anticipated to reach $83 billion by 2024, and
- Epilepsy
- The market for epilepsy
treatment is anticipated to reach $9 billion by 2022.
Cannabis Research
Methodology
KALY,
through its subsidiary NCMB focuses on the use of specific cannabis
extracts alone, and also along with using a proprietary process
which combines molecules of already proven therapeutic utility to
combat a variety of clinical disorders. In recognition of the
need to standardize candidate products and to determine mechanisms
for action with scientific credibility, KALY has established
collaborations with other companies and with universities to
enhance understanding and provide scientific support to the
introduction of novel cannabis extract formulations for the
consumer marketplace.
KALY has
already published its COPD research and initiated a second stage of
research and development. Research reports on the first phase
of development for KALY’s cannabis compounds for Type 2 Diabetes,
Cancer Pain Management and Epilepsy are expected to be published
later this year.
To
accelerate development, KALY is developing key partners with an
emphasis on establishing joint ventures with existing
biopharmaceutical companies. The company has a $3.5 million
development plan for its next stage of development and management
is working diligently to fund that development plan through the
capital structure of partner companies.
Beyond The Initial Four
Therapies
Beyond the
four specific cannabis therapies currently in various stages of
research and development, KALY has a number of additional target
therapies in its research pipeline. KALY’s proprietary extracts
have been evaluated in a genomic study where the extracts have
exhibited remarkable activity in gene arrays by up or down
regulating individual genes by as much as 200 fold. Genes
appearing especially sensitive to the introduction of KALY’s
cannabis extracts were associated with inflammation, healing and
cancer inhibition. The results of the genomic studies have
served to initiate planning for a host of additional therapies that
can be developed from KALY’s proprietary cannabis
extracts.
$1
Million 2019 Revenue Target From Parallel Revenue
Strategy
KALY is
not relying on its biopharmaceutical development strategy alone to
insure the company’s long-term success. With the popularity
of cannabis extracts for infusion into various consumer products,
KALY’s patented extraction process offers arguably the highest
quality extract to the infusion market. Drawing on KALY’s
patented cannabis extraction expertise, Puration’s (USOTC:
PURA) EVERx CBD Sports Water is already the leading CBD infused
beverage for the sports nutrition market. KALY has also
introduced its own CBD confections line, Hemp4mula with CBD infused
gum already on the market and gummies on the way. Hemp4mula
is expected to be available on the Ecommerce site USMJ.com hosted by North American Cannabis
Holdings, Inc. (USOTC:
USMJ) (aka USMJ). KALY has also entered into a
partnership with Nouveau (USOTC:
NOUV), a cannabis cultivation company, with plans to develop a
proprietary cannabis cultivar that can further enhance the quality
of KALY’s extracts. KALY’s consumer revenue strategy offers a
business line that can stand alone, but one that also provides KALY
with the long-term staying power to take the necessary time to
bring its cannabis extract biopharmaceutical products to
market. Currently, KALY management anticipates that its $1
million 2019 revenue goal for its parallel consumersmarket strategy
is well within reach.
To learn more about the company
visit https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024